Indian Journal of Endocrinology and Metabolism

ORIGINAL ARTICLE
Year
: 2013  |  Volume : 17  |  Issue : 1  |  Page : 91--94

Clinical experience with exenatide in obese North Indian patients with type 2 diabetes mellitus


Tarunika Bawa1, Vibha Dhingra2, Nidhi Malhotra1, Jasjeet S Wasir3, Ambrish Mithal3 
1 Department of Endocrinology, Indraprastha Apollo Hospital, Delhi, India
2 Clinical Research, Indraprastha Apollo Hospital, Delhi, India
3 Division of Endocrinology and Diabetes, Medanta, The Medicity, Gurgaon, India

Correspondence Address:
Jasjeet S Wasir
Consultant, Division of Endocrinology and Diabetes, Medanta, The Medicity, Gurgaon (Delhi NCR), Haryana 122001
India

Objective: To share our clinical experience with exenatide in obese North Indian subjects with type 2 diabetes. Materials and Methods: We share our experience with use of exenatide in 74 patients treated at Indraprastha Apollo Hospital, a tertiary care centre in New Delhi, India Subjects included obese / overweight subjects (mean weight and BMI; 97.67 ± 5.6 kg and 34.56 kg/m 2 ) with known history of type 2 DM (Mean: 9 ± 5.6 years) and maintaining suboptimal glycemic control (HbA1c >7%) on oral antidiabetic agents, with or without basal insulin. Metformin and sulphonylureas were continued (with dose adjustment if indicated), as was basal insulin (glargine / detemir). TZDs and DPP4 inhibitors were discontinued. The dose of exenatide was increased to 10 mcg twice a day after 4-12 weeks. 56 patients completed minimum 3 month therapy. 42 patients completed 6 months, 32, 9 months and 25 completed 12 months. Data of patients who had completed at-least 3 months of therapy was included for analysis. Results and Discussion: 69.77, 67.44, and 13.95% of the patients were receiving metformin, secretagogues or thiazolidinediones alone or in combination; 17.76% of the patients were on basal insulin. The change in fasting and post-prandial blood glucose levels were significant at 3, 6, 9 and 12 months with p0 -value <0.05. The mean weight loss at one, three, and six months and one year was 1.7 ± 1.3, 3.8 ± 2.5, 6.3 ± 3.4, and 8.3 ± 4.3 kg, respectively (P <0.05). The mean HbA1c (baseline: 8.8 ± 1.3%) at 3, 6 months and at one year was 7.8 ± 0.9, 7.7 ± 0.8 and 7.2 ± 0.8 (P <0.05). Thirty-five percent of the patients had a «SQ»good«SQ» A1c value (< 7%) at the end of 12 months. 13 patients discontinued exenatide (three due to lack of response, six due to cost of therapy and four due to severe nausea). Nausea was the most common side effect, occurring in 95% patients within 1 month, although the incidence declined with passage of time. Conclusions: Clinical use of Exenatide is associated with significant improvement in glycemic control and major weight loss (8.3±4.3 kg at 1 year) in obese subjects with type 2 diabetes. Nausea is the most common side effect. In conclusion, exenatide is a effective and useful option for treatment of type 2 diabetes in obese Indian subjects.


How to cite this article:
Bawa T, Dhingra V, Malhotra N, Wasir JS, Mithal A. Clinical experience with exenatide in obese North Indian patients with type 2 diabetes mellitus.Indian J Endocr Metab 2013;17:91-94


How to cite this URL:
Bawa T, Dhingra V, Malhotra N, Wasir JS, Mithal A. Clinical experience with exenatide in obese North Indian patients with type 2 diabetes mellitus. Indian J Endocr Metab [serial online] 2013 [cited 2020 Mar 31 ];17:91-94
Available from: http://www.ijem.in/article.asp?issn=2230-8210;year=2013;volume=17;issue=1;spage=91;epage=94;aulast=Bawa;type=0